Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel targets
BA211 Dual-indication*
Solid Tumor ProgramANNUAL Addressable METASTATIC US Patients> 10,000HLA-A2+
Target AND EngagerTC11αCD3 TCE
Discovery
COMPLETETarget identification and validation complete
Lead Optimisation
COMPLETEOptimising lead compounds for efficacy and safety
IND Enabling
IN PROGRESSPreclinical studies and regulatory preparation
Status
DC Selected2026
IND1H27
BA225 Multi-indication*
Solid Tumor ProgramANNUAL Addressable METASTATIC US Patients> 60,000HLA-A2+
Target AND EngagerTC11αCD3 TCE
Discovery
COMPLETETarget identification and validation complete
Lead Optimisation
IN PROGRESSOptimising lead compounds for efficacy and safety
IND Enabling
PENDINGPreclinical studies and regulatory preparation
Status
DC Selected1H26
IND2H27
BA2168 Multi-indication*
Solid Tumor ProgramANNUAL Addressable METASTATIC US Patients> 60,000HLA-A2+
Target AND EngagerTC168Undisclosed
Discovery
COMPLETETarget identification and validation complete
Lead Optimisation
IN PROGRESSOptimising lead compounds for efficacy and safety
IND Enabling
PENDINGPreclinical studies and regulatory preparation
Status
DC Selected2026
IND2027